health
Blood test combining microRNAs and CA19-9 shows potential for early pancreatic cancer detection
An international prospective study evaluated a blood assay that combines a 10-microRNA signature with carbohydrate antigen 19-9 for detecting early pancreatic ductal adenocarcinoma. The composite PANXEON score showed 86.8% sensitivity for stage I–II disease in the testing cohort, but the researchers say larger prospective studies are still needed.